HART-CT logo

HART-CT

In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, red

HART-CT

In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, red
Funding Gilead Pharmaceuticals
Portfolio Clinical Specialties
Interventions Medicine
Randomised Yes
Status Funding awarded/in set-up
Start Date 01-Jan-0001

There is currently an unmet need in cardiovascular disease prevention in patients diagnosed with HIV. This is attributable to longer life expectancy with HIV patients succumbing to traditional age-related diseases. The complex interplay of risk factors, chronic inflammation and antiretroviral therapy drives the significantly increased prevalence of cardiovascular disease in this group.

Publications

  • N/A